Overall, predicting that CTRED links amyloid–tau neurodegeneration to a vascular–iron dimension creates a scalable, interpretable bridge “from microbleeds to iron” in Alzheimer’s disease biomarkers and therapies. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.